Miransertib (ARQ 092), an orally-available, selective Akt inhibitor is effective against Leishmania
Author:
Funder
Canadian Institutes for Health Research
ArQule, Inc
Publisher
Public Library of Science (PLoS)
Subject
Multidisciplinary
Reference33 articles.
1. Leishmaniasis worldwide and global estimates of its incidence;J Alvar;PLoS One,2012
2. Drug resistance in leishmaniasis;SL Croft;Clin Microbiol Rev,2006
3. Recent advances in leishmaniasis treatment;TS Tiuman;Int J Infect Dis,2011
4. Mechanisms of immune evasion in leishmaniasis;G Gupta;Adv Appl Microbiol,2013
5. Myeloid cell IL-10 production in response to leishmania involves inactivation of glycogen synthase kinase-3beta downstream of phosphatidylinositol-3 kinase;D Nandan;J Immunol,2012
Cited by 19 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. A conserved role for AKT in the replication of emerging flaviviruses in vertebrates and vectors;Virus Research;2024-10
2. Exploring Radioiodinated Anastrozole and Epirubicin as AKT1-Targeted Radiopharmaceuticals in Breast Cancer: In Silico Analysis and Potential Therapeutic Effect with Functional Nuclear Imagining Implications;Molecules;2024-09-04
3. Repurposing of conformationally-restricted cyclopentane-based AKT–inhibitors leads to discovery of potential and more selective antileishmanial agents than miltefosine;Bioorganic Chemistry;2023-12
4. Inhibitors of phosphoinositide 3-kinase (PI3K) and phosphoinositide 3-kinase-related protein kinase family (PIKK);Journal of Enzyme Inhibition and Medicinal Chemistry;2023-07-24
5. Anti-leishmanial therapy: Caught between drugs and immune targets;Experimental Parasitology;2023-02
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3